Tarsus Pharmaceuticals has completed enrollment in the second pivotal phase 3 trial investigating TP-03 for the treatment of Demodex blepharitis and secured a $175 million credit facility, according to a press release.
The randomized, controlled, double-masked Saturn-2 trial is evaluating the efficacy and safety of TP-03 (lotilaner ophthalmic solution 0.25%) in 408 participants with Demodex blepharitis. The primary endpoint is the proportion of patients to experience complete collarette cure, which is being defined as zero to two collarettes per lid.
“We are committed to developing a